
**2017 OPTIONS FOR INDIVIDUAL MEASURES:**
REGISTRY ONLY

**MEASURE TYPE:**
Process

**DESCRIPTION:**
Percentage of patients aged 18 years and older, seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period who had baseline flow cytometry studies performed and documented in the chart.

**INSTRUCTIONS:**
This measure is to be reported a minimum of once per performance period for all chronic lymphocytic leukemia (CLL) patients seen during the performance period, regardless of when the diagnosis of CLL is made; the quality action being measured is that the baseline flow cytometry study occurred for each patient with CLL at the time of diagnosis or prior to initiating treatment. It is anticipated that eligible clinicians who provide services for patients with the diagnosis of chronic lymphocytic leukemia (not in remission) will submit this measure.

**Measure Reporting:**
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**
All patients aged 18 years and older, seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period

<table>
<thead>
<tr>
<th>Denominator Criteria (Eligible Cases):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients aged ≥ 18 years on date of encounter</td>
</tr>
<tr>
<td><strong>AND</strong> Diagnosis for CLL – not in remission (ICD-10-CM): C91.10, C91.12</td>
</tr>
<tr>
<td><strong>AND</strong> Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215</td>
</tr>
<tr>
<td><strong>WITHOUT</strong> Telehealth Modifier: GQ, GT</td>
</tr>
</tbody>
</table>

**NUMERATOR:**
Patients who had baseline flow cytometry studies performed and documented in the chart

<table>
<thead>
<tr>
<th>Definition:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Flow Cytometry Studies – Refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include anti-neoplastic therapy.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Numerator Options:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Met:</td>
</tr>
<tr>
<td>Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (3170F)</td>
</tr>
</tbody>
</table>

OR
Denominator Exception: Documentation of medical reason(s) for not performing baseline flow cytometry studies (3170F with 1P)

OR
Denominator Exception: Documentation of patient reason(s) for not performing baseline flow cytometry studies (eg, receiving palliative care or not receiving treatment as defined above) (3170F with 2P)

OR
Denominator Exception: Documentation of system reason(s) for not performing baseline flow cytometry studies (eg, patient previously treated by another physician at the time baseline flow cytometry studies were performed) (3170F with 3P)

OR
Performance Not Met: Flow cytometry studies not performed at time of diagnosis or prior to initiating treatment, reason not otherwise specified (3170F with 8P)

RATIONALE:
Due to the distinct pattern of protein antigens expressed in CLL, flow cytometry should be performed in order to confirm the diagnosis, correctly characterize the pathological cells, and determine prognosis. In some instances, flow cytometry may also offer additional therapeutically relevant information. (DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry studies in the chronic lymphoid leukemias. Semin Oncol. 1998;25(1):6-10.)

CLINICAL RECOMMENDATION STATEMENTS:
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines:

Adequate immunophenotyping is required to establish the diagnosis of CLL/SLL. Flow cytometry of peripheral blood is adequate for the diagnosis of CLL, and a biopsy is generally not required. (Category 2A Recommendation) (NCCN, 2016)

COPYRIGHT:
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the PCPI® Foundation (PCPI®) or American Society of Hematology (ASH). Neither ASH, nor the American Medical Association (AMA), nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.

The AMA’s and AMA-PCPI’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. ASH is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of August 15, 2014.

ASH encourages use of the Measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2016 PCPI® Foundation and American Society of Hematology. All Rights Reserved.
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2017 Registry Individual Measure Flow

#70 NQF #0379: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Start

Denominator

Patient Age at Date of Service > 18 years

Yes

Flow Cytometry Studies Performed at Time of Diagnosis or Prior to Initiating Treatment

No

Numerator

Data Completeness Met + Performance Met 3170F or equivalent (4 patients)

Data Completeness Met + Denominator Exception 3170F-1P or equivalent (1 patient)

Data Completeness Met + Denominator Exception 3170F-2P or equivalent (0 patients)

Data Completeness Met + Denominator Exception 3170F-3P or equivalent (0 patients)

Data Completeness Met + Performance Not Met 3170F-8P or equivalent (2 patients)

Data Completeness Not Met Quality-Data Code or equivalent not reported (1 patient)

Not Included in Eligible Population/Denominator*

Yes

Diagnosis for CLL (Not in Remission) as Listed in Denominator*

No

Documentation of Medical Reason(s) for Not Performing Baseline Flow Cytometry Studies

Yes

Encounter as Listed in Denominator* (1/1/2017 thru 12/31/2017)

No

Telehealth Modifier: GQ, GT

Yes

Include in Eligible Population/Denominator (8 patients)

No

SAMPLE CALCULATIONS:

Data Completeness=

\[
\text{Performance Met (a=4 patients) + Denominator Exception (b^1+b^2+b^3=1 patient) + Performance Not Met (c=2 patients)} = \frac{\text{7 patients}}{\text{8 patients}} = 87.50\%
\]

\[
\text{Performance Rate=} \quad \text{Performance Met (a=4 patients)} = \frac{\text{4 patients}}{\text{6 patients}} = 66.67\%
\]

Data Completeness Numerator (7 patients) - Denominator Exception (b^1+b^2+b^3=1 patient) = 6 patients

*See the posted Measure Specification for specific coding and instructions to report this measure

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
2017 Registry Individual Measure Flow
#70 NQF #0379: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator

2. Check Patient Age:
   a. If Patient Age is greater than or equal to 18 years of age at Date of Service equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
   b. If Patient Age is greater than or equal to 18 years of age at Date of Service equals Yes during the measurement period, proceed to check Patient Diagnosis.

3. Check Patient Diagnosis:
   a. If Diagnosis of CLL (Not in Remission) as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Diagnosis of CLL (Not in Remission) as Listed in the Denominator equals Yes, proceed to check Encounter Performed.

4. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.

5. Check Telehealth Modifier:
   a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing.
   b. If Telehealth Modifier equals No, include in the Eligible population.

6. Denominator Population:
   a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.

7. Start Numerator

8. Check Baseline Flow Cytometry Studies Performed at Time of Diagnosis or Prior to Initiating Treatment:
   a. If Baseline Flow Cytometry Studies Performed at Time of Diagnosis or Prior to Initiating Treatment equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 4 patients in Sample Calculation.
   c. If Baseline Flow Cytometry Studies Performed at Time of Diagnosis or Prior to Initiating Treatment equals No, proceed to Documentation of Medical Reason(s) for Not Performing Baseline Flow Cytometry Studies.
9. Check Documentation of Medical Reason(s) for Not Performing Baseline Flow Cytometry Studies:
   a. If Documentation of Medical Reason(s) for Not Performing Baseline Flow Cytometry Studies equals Yes, include in Data Completeness Met and Denominator Exception.
   b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b1 equals 1 patient in the Sample Calculation.
   c. If Documentation of Medical Reason(s) for Not Performing Baseline Flow Cytometry Studies equals No, proceed to Documentation of Patient Reason(s) for Not Performing Baseline Flow Cytometry Studies.

10. Check Documentation of Patient Reason(s) for Not Performing Baseline Flow Cytometry Studies:
    a. If Documentation of Patient Reason(s) for Not Performing Baseline Flow Cytometry Studies equals Yes, include in Data Completeness Met and Denominator Exception.
    b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b2 equals 0 patients in the Sample Calculation.
    c. If Documentation of Patient Reason(s) for Not Performing Baseline Flow Cytometry Studies equals No, proceed to Documentation of System Reason(s) for Not Performing Baseline Flow Cytometry Studies.

11. Check Documentation of System Reason(s) for Not Performing Baseline Flow Cytometry Studies:
    a. If Documentation of System Reason(s) for Not Performing Baseline Flow Cytometry Studies equals Yes, include in Data Completeness Met and Denominator Exception.
    b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b3 equals 0 patients in the Sample Calculation.
    c. If Documentation of System Reason(s) for Not Performing Baseline Flow Cytometry Studies equals No, proceed to Baseline Flow Cytometry Studies Not Performed at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified.

12. Check Baseline Flow Cytometry Studies Not Performed at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified:
    a. If Baseline Flow Cytometry Studies Not Performed at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified equals Yes, include in Data Completeness Met and Performance Not Met.
    b. Data Completeness Met and Performance not met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 2 patients in the Sample Calculation.
    c. If Baseline Flow Cytometry Studies Not Performed at Time of Diagnosis or Prior to Initiating Treatment, Reason Not Specified equals No, proceed to Data Completeness Not Met.

13. Check Data Completeness Not Met:
    a. If Data Completeness Not Met, the Quality Data Code or equivalent was not reported. 1 patient has been subtracted from the data completeness numerator in sample calculation.
### SAMPLE CALCULATIONS:

Data Completeness:

- Performance Met (a=4 patients) + Denominator Exception (b + c + d = 1 patient) + Performance Not Met (c=2 patients) = 7 patients = 87.50%  
- Eligible Population / Denominator (d=8 patients) = 8 patients

<table>
<thead>
<tr>
<th>Performance Rate</th>
<th>Performance Met (a=4 patients)</th>
<th>4 patients = 66.67%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Completeness Numerator (7 patients) - Denominator Exception (b + c + d = 1 patient)</td>
<td>6 patients</td>
<td></td>
</tr>
</tbody>
</table>

Version 1.0
11/15/2016

CPT only copyright 2016 American Medical Association. All rights reserved.
Page 7 of 7